Late-Onset Aicardi-Goutières Syndrome: A Characterization of Presenting Clinical Features
Cara Piccoli(Children's Hospital of Philadelphia), Laura Adang(Children's Hospital of Philadelphia), Simona Orcesi(Fondazione Istituto Neurologico Nazionale Casimiro Mondino), Arastoo Vossough(Children's Hospital of Philadelphia), Adeline Vanderver(Children's Hospital of Philadelphia), Jessica Galli(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), Davide Tonduti, Costanza Varesio(University of Pavia), Silvia Masnada(University of Pavia), Francesco Gavazzi(Children's Hospital of Philadelphia), Elisa Fazzi(Centro Studi GISED), Valentina De Giorgis(Fondazione Istituto Neurologico Nazionale Casimiro Mondino), Nowa Bronner(Children's Hospital of Philadelphia), Micaela De Simone(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), Holly Dubbs
Cited by 44
Related Papers
Assessment of interferon-related biomarkers in Aicardi-Goutières syndrome associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR: a case-control study
|The Lancet Neurology|2013|441
Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study
|The Lancet Neurology|2020|326
Janus Kinase Inhibition in the Aicardi–Goutières Syndrome
|New England Journal of Medicine|2020|201